Skip to main content
Online CJC-1295

An accessible, plain-language digest of what the published CJC-1295 research actually shows on the growth-hormone / IGF-1 axis - laid out as a curated board of the studies, the kinetics, and the honest data gaps.

The papers behind the study findings

CJC-1295 references and ways to find them

You’ll find each title, author list, journal, and year here. I’ll also explain the two paper-search codes.

Go back to the findingsSee what this guide does

How can you use this paper list?

Researchers made CJC-1295 as a test drug for changing growth hormones. You’ll find the papers here. Two papers published in 2006 hold the results. One of those 2006 papers explains the men’s brief hormone releases. Together, they report how growth hormone and IGF-1, the insulin-like growth factor, rose and the 5.8-8.1 day time for the body to clear half the long form.

Rat work from 2005 explains how the drug joins the blood protein albumin. A 2006 mouse study covers growth, and a 2009 paper covers blood proteins. A 2025 review looks back across related work. These papers don’t show better health or settle safety over many years.

Each entry names the journal and year. PMID is the paper’s number in a medical library, while DOI is its lasting online code. If a number surprised me, I’d search either code or ask a librarian, so you can read the paper yourself and decide whether its finding answers your own question.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
  4. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
  5. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced GH secretion. Endocrinology. 2002. ↗
  6. Greater efficacy of episodic than continuous growth hormone-releasing hormone (GHRH) administration on GH release. J Clin Endocrinol Metab. 1996;81(3). ↗
  7. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  8. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. ↗
  9. (2026 peptide therapy safety review). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal conditions. Sports Med. 2026. ↗
  10. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. ↗
  11. (GH sodium-retention study). GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron. J Clin Endocrinol Metab. 2002. ↗
  12. (GHRH analog pulsatility/insulin study). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. J Clin Endocrinol Metab. 2011. ↗
  13. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) meeting - briefing document on growth hormone secretagogues (CJC-1295). FDA Advisory Committee Briefing Materials. 2024. ↗
  14. ConjuChem Inc. (trial sponsor). A study to evaluate CJC-1295 in HIV patients with visceral obesity. ClinicalTrials.gov. 2006. ↗
  15. Reference summary. Modified GRF (1-29) - chemical and pharmacological description. Encyclopedic reference. 2024. ↗
  16. World Anti-Doping Agency. The Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA International Standard. 2025. ↗